AKEBIA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • March 4th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ] by and between Akebia Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
Shares AKEBIA THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.00001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • March 4th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTRights Agreement • March 4th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the [—] day of February, 2014 by and among AKEBIA THERAPEUTICS, INC., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and collectively, the “Investors”), and any Additional Investor that becomes a party to this Agreement in accordance with Section 6.9 hereof.
STOCK OPTION AWARD granted under the AKEBIA THERAPEUTICS, INC. NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • March 4th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations
This agreement (the “Agreement”) evidences a stock option granted by Akebia Therapeutics, Inc. (the “Company”) to the undersigned (the “Optionee”), pursuant to and subject to the terms of the Akebia Therapeutics, Inc. 2014 Incentive Plan (the “Plan”).
EXECUTIVE SEVERANCE AGREEMENTExecutive Severance Agreement • March 4th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This EXECUTIVE SEVERANCE AGREEMENT (the “Agreement”) is entered into as of the day of , 2014 (the “Effective Date”), by and between Akebia Therapeutics, Inc., a Delaware corporation (“Akebia” or the “Company”), and [FULL LEGAL NAME], a resident of the [State] [Commonwealth] of (the “Executive”).
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. MASTER SERVICES AGREEMENTMaster Services Agreement • March 4th, 2014 • Akebia Therapeutics, Inc. • Pharmaceutical preparations • New York
This Proposal for Manufacturing 350kg of AKB-6548 is, effective as of the date of the latest signature below, made part of that Master Services Agreement by and between Evonik Corporation (“Evonik”) and Akebia Therapeutics, Inc. (“Customer”) dated as of March 3, 2014 (“MSA”) and is a Proposal under the MSA, subject to all of the terms and conditions therein. Capitalized terms used, but not otherwise defined, in this Proposal shall have the meaning set forth in the MSA.
